N ATALIZUMAB (NAT), AN approved treatment for relapsing-remitting multiple sclerosis (MS) (comarketed by Biogen Idec and É lan as Tysabri), is a recombinant humanized monoclonal IgG4 antibody directed against the ␣4-subunit of VLA-4. We and others [1] [2] [3] have shown that management of patients with relapsingremitting MS treated with NAT leads to a rapid and sustained increase in circulating CD34 ϩ cells. A recent study 4 in a small cohort of 8 MS patients was suggestive of mobilization of CD34 ϩ cells out of the bone marrow (BM).
However, increased numbers of CD34 ϩ cells in the peripheral blood (PB) could alternatively be the result of impaired homing of CD34 ϩ cells to, rather than true mobilization of, the BM in patients treated with NAT. We addressed this by assessing the adhesive and migratory capacity of CD34 ϩ cells in PB relevant for transendothelial egress in a cohort of MS patients treated with NAT. In addition, we studied the effect of NAT on coexpression of CD49d (␣4-subunit of VLA-4) on and adhesive properties of BM CD34 ϩ cells, the BM cellularity, the proportion of BM CD34 ϩ cells, and JC (John Cunningham) virus DNA expression in BM aspirates of 9 MS patients and 8 healthy age-and sex-matched control patients. From our results, we conclude that CD34 ϩ cells exposed to NAT in the PB are functionally impaired, whereas the CD34 ϩ cells in the BM appear to be only marginally affected by the antibody. This argues against the use of NAT as an agent to mobilize hematopoietic progenitor cells. Furthermore, patients with relapsingremitting MS appear not to be at risk of exhaustion of the CD34 ϩ hematopoietic progenitor pool as a potential adverse effect of long-term treatment. In addition, the present findings add to recent data arguing against a BM release hypothesis in the pathogenesis of progressive multifocal leukoencephalopathy observed in MS patients treated with NAT. 
METHODS
Fifty-two patients with relapsing-remitting MS, receiving NAT once every month (median [range] number of infusions, 7 ), were included. Informed consent was obtained following the guidelines of the local ethics committee of Heinrich-Heine-University (Dü sseldorf, Germany) in accordance with the Declaration of Helsinki. Before NAT infusion, 50 mL of EDTA-anticoagulated PB was collected.
Peripheral blood mononuclear cells were obtained by density centrifugation using density gradient media (lymphoprep; Technoclone GmbH, Vienna, Austria) as previously described. 8 The CD34 ϩ cells were separated by midiMACS magnetic separation system (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as previously published. 9 The CD34 ϩ cells purified from leukapheresis products of 24 healthy donors, who had received a 4-to 5-day course of granulocyte colonystimulating factor (G-CSF), served as control patients.
Bone marrow aspirates were obtained from 9 patients before NAT infusion (median interval after the last NAT administration, 28 days) and from 8 healthy controls (HCs). The CD34 ϩ cells were positively selected after density gradient centrifugation as previously described. 10 The proportion of CD34 ϩ cells of BM samples were assessed after red blood cell lysis using fluorescence-activated cell sorting analysis. The BM cellularity (number of mononuclear cells per microliter) was measured by the computed mononuclear cells after density centrifugation, taking into account the volume of the BM aspirate. Median (SEM) purity measured by flow cytometry was 97.1% (0.6%) for NAT samples and 97.8% (2.7%) for HC samples. Flow cytometric analysis, cell adhesion tests, and migration assays of selected CD34 ϩ cells were performed as previously described. [11] [12] [13] Long-term culture-initiating assays were performed in accordance with described methods 14, 15 with modifications. Polymerase chain reaction assays for JC virus DNA of CD34 ϩ separates were performed as previously published. 3 Flow cytometric analysis of the cell cycle and cellular DNA content as well as of the phosphatidylserine expression were performed as described previously 16, 17 to detect apoptotic CD34 ϩ cells. Statistical analysis was performed using SPSS statistical software, version 18 (IBM, Armonk, New York).
RESULTS

Circulating CD34
ϩ cells of patients treated with NAT were more mature, showed impaired adhesive and migratory properties, and showed no increase in the rate of apoptosis. Circulating CD34 ϩ cells of MS patients treated with NAT (NAT group) were compared with those of HCs mobilized by G-CSF (G-CSF group). The phenotype of circulating CD34 (Figure 3) .
The adhesive abilities of BM CD34 ϩ cells of NATtreated patients remain unaffected, whereas the migratory properties are impaired. We observed no significant difference in the median (SEM) (Figure 2 ).
The JC virus DNA was not detectable in BM CD34 ϩ cells of 9 MS patients treated with NAT. This was demonstrated by polymerase chain reaction assay.
COMMENT
Treatment of MS patients with NAT leads to a rapid and sustained increase in circulating CD34 ϩ cells in the PB.
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Here, we present data showing that this increase is the result of impaired homing of CD34 ϩ cells to, rather than true mobilization of, the BM. Therefore, we believe that the increased concentration of CD34 ϩ cells in the PB is the result of a gradual accumulation of cells unable to return to homing sites, such as the BM. The following data support this view: (1) circulating CD34 ϩ cells of MS patients treated with NAT revealed reduced adhesive and migratory properties; thus, transendothelial egress relevant for homing is most likely to be impaired; (2) adhesive properties of BM CD34 ϩ cells are not impaired, whereas migratory capacity is reduced; thus, BM CD34 ϩ cells are less likely to get mobilized out of the BM; (3) the BM cellularity and the proportion of BM CD34 ϩ cells are not affected by treatment with NAT; thus, NAT treatment appears to have only a marginal influence on BM in our cohort.
These findings have implications for the clinical use of NAT in the treatment of MS, as well as for NAT as a potential agent to mobilize hematopoietic progenitor cells in hematology. First, coexpression analysis demonstrates that circulating CD34 ϩ cells of MS patients treated with NAT are more mature and therefore have a poor ability to initiate long-term cultures. Thus, NAT is not a promising candidate to mobilize hematopoietic progenitors in hematology. Second, our findings argue against an antibody-induced exhaustion of the CD34 ϩ progenitor pool as a potential adverse effect of longterm application of NAT in MS patients. Third, the BM has been hypothesized to be a relevant reservoir for the JC virus and the cases of progressive multifocal leukoencephalopathy observed in MS patients treated with NAT. 3, 6, 7 We were unable to detect the JC virus in BM CD34 ϩ cells within this study. We cannot exclude a sampling error in only 9 MS patients. However, the fact that NAT treatment impairs homing strongly argues against a hypothesis claiming NAT induced mobilized JC virus-infected BM cells to be involved in progressive multifocal leukoencephalopathy pathogenesis. This finding is in line with negative JC virus DNA findings in circulating CD34 ϩ cells in a recently published study. 3 Thus, other mechanisms of JC virus reactivation and central nervous system infection should be addressed to understand NAT-associated cases of progressive multifocal leukoencephalopathy. 
